CARY, N.C.–(BUSINESS WIRE)–Biologics,
Inc. has been selected by Clovis Oncology, Inc. to be a specialty
pharmacy provider in the limited distribution network for RUBRACATM
Approved by the U.S. Food and Drug Administration (FDA) on December 19,
2016, RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor
indicated as monotherapy for the treatment of patients with deleterious
BRCA mutation (germline and/or somatic) associated advanced ovarian
cancer who have been treated with two or more chemotherapies. Patients
should be selected for therapy based on an FDA-approved companion
diagnostic for RUBRACA. RUBRACA was granted Breakthrough Therapy
designation and Priority Review by the FDA.
“We are honored to be included in the limited distribution network for
RUBRACA,” said Brandon Tom, vice president, Biopharma Services,
Biologics, Inc. “We will be able to draw on our experience in ovarian
cancer care to provide high-touch clinical support and improve outcomes
for this patient population.”
RUBRACA is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3.
Data from two clinical trials testing the efficacy of RUBRACA in
patients with advanced BRCA-mutant ovarian cancer who had progressed
after two or more prior chemotherapies showed an overall Objective
Response Rate (ORR) of 54% and a median duration response of 9.2 months.
The ORR was similar for patients with germline BRCA-mutant ovarian
cancer or somatic BRCA-mutant ovarian cancer and for patients with a
BRCA1 gene mutation or BRCA2 gene mutationi.
About 22,000 women are diagnosed with ovarian cancer in the U.S. each
year, ranking it fifth in cancer deathsi. About 25 percent of
women who are diagnosed with ovarian cancer have a germline or somatic
BRCA mutation, making treatments that target these mutations especially
important to this unique subset of patients.
Recognized for its high-touch patient care model, Biologics’
multidisciplinary care team provides individualized care plans to
address the unique clinical, financial and emotional needs of each
Physicians may submit prescriptions to Biologics via phone (800.850.4306),
fax (800.823.4506) or eScribe. For electronic
prescribing systems, physicians may search for Biologics within their
Biologics, Inc. is an oncology pharmacy services company that empowers
healthcare providers, payers and biopharma to optimize cancer care for
the best possible outcomes – clinical, financial and emotional. Unifying
fragmented healthcare services, Biologics brings efficiency and humanity
to oncology care management by focusing on the patient’s best interest
as the surest path to managing cost and risk.
Biologics is part of McKesson Specialty Health, a division of
McKesson Corporation, empowering the community patient care delivery
system by helping community practices advance the science, technology
and quality of care. Through innovative clinical research, business and
operational solutions, facilitated by integrated technology systems, we
focus on improving the financial health of our customers so they may
provide the best care to their patients. Our combined organization will
help better support patients and expedite access to oncology therapies.
For more information, visit www.mckessonspecialtyhealth.com
Allison Keenan, 800-850-4306